论文部分内容阅读
Celator制药有限公司CPX-351脂质体注射液,是阿糖胞苷(cytarabine)和柔红霉素(daunorubicin)按5∶1制成的纳米级脂质体胶囊注射液,治疗高危急性髓性白血病患者的Ⅲ期临床试验达到主终点,总存活改善达到统计学显著性。Ⅲ期临床试验在美国、加拿大39个试验点中入选309名60~75岁高危急性骨髓性白血病患
Celator Pharmaceutical Co., Ltd. CPX-351 liposomal injection of cytarabine and daunorubicin 5: 1 nano-scale liposome capsule injection for the treatment of high-risk acute myeloid The phase III clinical trial of leukemia patients reached the primary endpoint and the overall survival improvement was statistically significant. Phase Ⅲ clinical trials in the United States, Canada 39 test points were selected 309 60 to 75 years old high-risk acute myeloid leukemia